Article
Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Sept 1993
List A F, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W
Abstract excerpt
PURPOSE: To determine the toxicities and maximum-tolerated dose of cyclosporine (CsA) administered with daunorubicin as a modulator of multidrug resistance (MDR) in acute leukemia, and to evaluate response to treatment and its relationship to mdr1 gene expression. PATIENTS AND METHODS: Patients with poor-risk acute myeloid leukemia (AML) received sequential treatment with cytarabine (3 g/m2/d intravenously...
Topics
- ATP Binding Cassette Transporter, Subfamily B, Member 1
- Acute Disease
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
- Carrier Proteins
- Child
- Child, Preschool
- Cyclosporine